-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
The -X- _ O
parasitic -X- _ O
disease -X- _ O
malaria -X- _ O
remains -X- _ O
a -X- _ O
major -X- _ O
global -X- _ O
public -X- _ O
health -X- _ O
concern -X- _ O
and -X- _ O
no -X- _ O
truly -X- _ O
effective -X- _ O
vaccine -X- _ O
exists. -X- _ O
One -X- _ O
approach -X- _ O
to -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
a -X- _ O
malaria -X- _ O
vaccine -X- _ O
is -X- _ O
to -X- _ O
target -X- _ O
the -X- _ O
asexual -X- _ O
blood -X- _ O
stage -X- _ O
that -X- _ O
results -X- _ O
in -X- _ O
clinical -X- _ O
symptoms. -X- _ O
Most -X- _ O
attempts -X- _ O
have -X- _ O
failed. -X- _ O
New -X- _ O
antigens -X- _ O
such -X- _ O
as -X- _ O
P27A -X- _ O
and -X- _ O
P27 -X- _ O
have -X- _ O
emerged -X- _ O
as -X- _ O
potential -X- _ O
new -X- _ O
vaccine -X- _ O
candidates. -X- _ O
Multiple -X- _ O
studies -X- _ O
have -X- _ O
demonstrated -X- _ O
that -X- _ O
antigens -X- _ O
are -X- _ O
more -X- _ O
immunogenic -X- _ O
and -X- _ O
are -X- _ O
better -X- _ O
correlated -X- _ O
with -X- _ O
protection -X- _ O
when -X- _ O
presented -X- _ O
on -X- _ O
particulate -X- _ O
delivery -X- _ O
systems. -X- _ O
One -X- _ O
such -X- _ O
particulate -X- _ O
delivery -X- _ O
system -X- _ O
is -X- _ O
the -X- _ O
self-assembling -X- _ O
protein -X- _ O
nanoparticle -X- _ O
( -X- _ O
SAPN -X- _ O
) -X- _ O
that -X- _ O
relies -X- _ O
on -X- _ O
coiled-coil -X- _ O
domains -X- _ O
of -X- _ O
proteins -X- _ O
to -X- _ O
form -X- _ O
stable -X- _ O
nanoparticles. -X- _ O
In -X- _ O
the -X- _ O
past -X- _ O
we -X- _ O
have -X- _ O
used -X- _ O
de -X- _ O
novo -X- _ O
designed -X- _ O
amino -X- _ O
acid -X- _ O
domains -X- _ O
to -X- _ O
drive -X- _ O
the -X- _ O
formation -X- _ O
of -X- _ O
the -X- _ O
coiled-coil -X- _ O
scaffolds -X- _ O
which -X- _ O
present -X- _ O
the -X- _ O
antigenic -X- _ O
epitopes -X- _ O
on -X- _ O
the -X- _ O
particle -X- _ O
surface. -X- _ O
RESULTS -X- _ O
: -X- _ O
Here -X- _ O
we -X- _ O
use -X- _ O
naturally -X- _ O
occurring -X- _ O
domains -X- _ O
found -X- _ O
in -X- _ O
the -X- _ O
tex1 -X- _ O
protein -X- _ O
to -X- _ O
form -X- _ O
the -X- _ O
coiled-coil -X- _ O
scaffolding -X- _ O
of -X- _ O
the -X- _ O
nanoparticle. -X- _ O
Thus -X- _ O
, -X- _ O
by -X- _ O
engineering -X- _ O
P27A -X- _ O
and -X- _ O
a -X- _ O
new -X- _ O
extended -X- _ O
form -X- _ O
of -X- _ O
the -X- _ O
coiled-coil -X- _ O
domain -X- _ O
P27 -X- _ O
onto -X- _ O
the -X- _ O
N -X- _ O
and -X- _ O
C -X- _ O
terminus -X- _ O
of -X- _ O
the -X- _ O
SAPN -X- _ O
protein -X- _ O
monomer -X- _ O
we -X- _ O
have -X- _ O
developed -X- _ O
a -X- _ O
particulate -X- _ O
delivery -X- _ O
system -X- _ O
that -X- _ O
effectively -X- _ O
displays -X- _ O
both -X- _ O
antigens -X- _ O
on -X- _ O
a -X- _ O
single -X- _ O
particle -X- _ O
that -X- _ O
uses -X- _ O
malaria -X- _ O
tex1 -X- _ O
sequences -X- _ O
to -X- _ O
form -X- _ O
the -X- _ O
nanoparticle -X- _ O
scaffold. -X- _ O
These -X- _ O
particles -X- _ O
are -X- _ O
immunogenic -X- _ O
in -X- _ O
a -X- _ O
murine -X- _ O
model -X- _ O
and -X- _ O
induce -X- _ O
immune -X- _ O
responses -X- _ O
similar -X- _ O
to -X- _ O
the -X- _ O
ones -X- _ O
observed -X- _ O
in -X- _ O
seropositive -X- _ B-Patient
individuals -X- _ I-Patient
in -X- _ I-Patient
malaria -X- _ I-Patient
endemic -X- _ I-Patient
regions. -X- _ I-Patient
CONCLUSIONS -X- _ O
: -X- _ O
We -X- _ O
demonstrate -X- _ O
that -X- _ O
our -X- _ O
P27 -X- _ B-Intervention
/ -X- _ I-Intervention
P27A-SAPNs -X- _ I-Intervention
induce -X- _ O
an -X- _ O
immune -X- _ B-Outcome
response -X- _ I-Outcome
akin -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
one -X- _ I-Outcome
in -X- _ I-Outcome
seropositive -X- _ I-Outcome
individuals -X- _ I-Outcome
in -X- _ I-Outcome
Burkina -X- _ I-Outcome
Faso. -X- _ I-Outcome
Since -X- _ O
P27 -X- _ B-Outcome
is -X- _ I-Outcome
highly -X- _ I-Outcome
conserved -X- _ I-Outcome
among -X- _ I-Outcome
different -X- _ I-Outcome
Plasmodium -X- _ I-Outcome
species -X- _ I-Outcome
, -X- _ O
these -X- _ B-Outcome
novel -X- _ I-Outcome
SAPNs -X- _ I-Outcome
may -X- _ I-Outcome
even -X- _ I-Outcome
provide -X- _ I-Outcome
cross-protection -X- _ I-Outcome
between -X- _ I-Outcome
Plasmodium -X- _ I-Outcome
falciparum -X- _ I-Outcome
and -X- _ I-Outcome
Plasmodium -X- _ I-Outcome
vivax -X- _ I-Outcome
the -X- _ I-Outcome
two -X- _ I-Outcome
major -X- _ I-Outcome
human -X- _ I-Outcome
malaria -X- _ I-Outcome
pathogens. -X- _ I-Outcome
As -X- _ B-Outcome
the -X- _ I-Outcome
SAPNs -X- _ I-Outcome
are -X- _ I-Outcome
also -X- _ I-Outcome
easy -X- _ I-Outcome
to -X- _ I-Outcome
manufacture -X- _ I-Outcome
and -X- _ I-Outcome
store -X- _ I-Outcome
they -X- _ I-Outcome
can -X- _ I-Outcome
be -X- _ I-Outcome
delivered -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
population -X- _ I-Outcome
in -X- _ I-Outcome
need -X- _ I-Outcome
without -X- _ I-Outcome
complication -X- _ I-Outcome
thus -X- _ I-Outcome
providing -X- _ I-Outcome
a -X- _ I-Outcome
low -X- _ I-Outcome
cost -X- _ I-Outcome
malaria -X- _ I-Outcome
vaccine -X- _ I-Outcome
. -X- _ O

